疼痛难以缓解？FDA批准复方药片Seglentis用于严重的急性疼痛

Acute pain refers to unbearable severe pain caused by disease, trauma, etc. It can occur anywhere in the body and is more common in cancer pain. Acute pain usually occurs suddenly and is unbearable. In some severe cases, it is difficult to relieve it even with painkillers. The pain is really "terrible". A new type of compound pill is about to be launched, which will bring good news to these patients who are suffering from unbearable pain.

Celecoxib is a nonsteroidal anti-inflammatory drug and tramadol is an opioid agonist. Segletis contains 56 mg of celecoxib and 44 mg of tramadol.

Dr. Craig A. Sponseller, chief medical officer of Kowa Pharmaceuticals America, said: "Seglentis' unique cocrystal formulation provides effective pain relief through a multimodal approach."

Esteve Pharmaceuticals has reached an agreement with Kowa Pharmaceuticals America to launch the painkiller in the United States in early 2022.

"Seglentis employs 4 different and complementary analgesic mechanisms to treat acute pain in adults severe enough to require opioid analgesics and not adequately relieved by alternative therapies, providing an important option for health care providers and patients," Sponseller said.

Because of the risks of addiction, abuse and misuse of opioids, the FDA will require a Risk Evaluation and Mitigation Strategy (REMS) for Segletis, even when taking recommended doses.

The drug's label states that Segletis should be taken as two tablets every 12 hours as needed and for the shortest possible duration consistent with the individual patient's treatment goals.

Patients should be monitored for respiratory depression, particularly during the first 24 - 72 hours after starting treatment with Segletis.

Healthcare providers should discuss naloxone (Narcan) with their patients and consider prescribing the opioid antagonist naloxone based on the patient's risk factors for overdose.

References:

https://www.medscape.com/viewarticle/961177